These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32653044)

  • 21. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
    Ju C; Lai RWC; Li KHC; Hung JKF; Lai JCL; Ho J; Liu Y; Tsoi MF; Liu T; Cheung BMY; Wong ICK; Tam LS; Tse G
    Rheumatology (Oxford); 2020 Sep; 59(9):2340-2349. PubMed ID: 31873735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline.
    Shekelle PG; Newberry SJ; FitzGerald JD; Motala A; O'Hanlon CE; Tariq A; Okunogbe A; Han D; Shanman R
    Ann Intern Med; 2017 Jan; 166(1):37-51. PubMed ID: 27802478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease　- Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
    Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
    Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Class effect of xanthine oxidase inhibitors on flow-mediated dilatation in hypertensive patients: A randomized controlled trial.
    Hoshide S; Kabutoya T; Ueno H; Kario K
    J Clin Hypertens (Greenwich); 2020 Mar; 22(3):451-456. PubMed ID: 31873985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout.
    Helget LN; O'Dell JR; Newcomb JA; Androsenko M; Brophy MT; Davis-Karim A; England BR; Ferguson R; Pillinger MH; Neogi T; Palevsky PM; Wu H; Kramer B; Mikuls TR
    Arthritis Rheumatol; 2024 Apr; 76(4):638-646. PubMed ID: 37842953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Burden and management of gout in a multi-ethnic Asian cohort.
    Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
    Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Febuxostat for the chronic management of hyperuricemia in patients with gout.
    Chinchilla SP; Urionaguena I; Perez-Ruiz F
    Expert Rev Clin Pharmacol; 2016; 9(5):665-73. PubMed ID: 26942273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
    Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC
    Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on gout management: what is old and what is new.
    Afinogenova Y; Danve A; Neogi T
    Curr Opin Rheumatol; 2022 Mar; 34(2):118-124. PubMed ID: 34907116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Febuxostat for the treatment of hyperuricaemia in gout.
    Robinson PC; Dalbeth N
    Expert Opin Pharmacother; 2018 Aug; 19(11):1289-1299. PubMed ID: 30024787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy.
    Pascart T; Latourte A; Flipo RM; Chalès G; Coblentz-Baumann L; Cohen-Solal A; Ea HK; Grichy J; Letavernier E; Lioté F; Ottaviani S; Sigwalt P; Vandecandelaere G; Richette P; Bardin T
    Joint Bone Spine; 2020 Oct; 87(5):395-404. PubMed ID: 32422338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Debates in gout management.
    Abhishek A
    Curr Opin Rheumatol; 2020 Mar; 32(2):134-139. PubMed ID: 31842034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Febuxostat: a new treatment for hyperuricaemia in gout.
    Edwards NL
    Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout.
    Frampton JE
    Drugs; 2015 Mar; 75(4):427-38. PubMed ID: 25724536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.